Nice commentary summarizing the progress of the most promising HBOC formulations currently in (pre-)clinical trials.
Hemoglobin-based oxygen carrier: what we have learned and where we are heading?
doi.org/10.1093/proc...
Michelle Jansman
@michellejansman.bsky.social
324 followers 194 following 52 posts
Researcher at DTU Health Tech and Stanford School of Medicine | Nanoparticle formulation | Oxygen carriers | Tissue engineering
![Part of the article:
Peer review cannot realistically verify every reference. There simply is not enough time. Today, targeted AI tools could potentially help detect mis-citations or odd citation patterns, making the work more robust [4].
Journals should also offer a clear, low-friction process for post-publication corrections. A publication should not be set in stone after proofs. A formal reporting mechanism must allow authors to challenge and fix citation errors without needing the citing author’s approval.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:tqor7h2oefvnoze4k2dn6m5e/bafkreigq5fsoyprpgacyedyjza7y6grwjyzag2e3uzp3qxqdbzhxoygsk4)
![Paper: Nanoparticle O2 Carrier Composed of a Polymerized Stroma-Free Hemoglobin Core and Serum Albumin Shell as a Red Blood Cell Alternative in Hemorrhagic Shock Therapy, by Kohyama et al. 2025, ACS Applied bio materials. https://doi.org/10.1021/acsabm.4c01901
TOC showing SFHbNPs product in solution, schematic of the NP system and the in vivo model. Fig 3. (A) Visible absorption spectral changes of SFHbNP at 25 °C (in PBS, pH 7.4). (B) O2 dissociation curves of SFHbNP, Hb, and RBC at37 °C (in PBS, pH 7.4). Fig 4. Changes in (A) survival rate and (B) MAP in anesthetized rats during the hemorrhagic shock and following resuscitation with SFHbNP solution ([Hb] = 5 g dL−1, in PBS with 3 g dL−1 HSA, pH 7.4) and controls (SAB, RL).](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:tqor7h2oefvnoze4k2dn6m5e/bafkreifwwbg5bpwewmg4aoa6c3w6twd3aljolugvhyenjrwp6fixicfe6a)
